CTIS2022-502446-27-00招募中1 期
A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator’s Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide - 64407564MMY3009
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 827
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Be =18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place) at the time of informed consent., Documented multiple myeloma as defined by the criteria below: a. Multiple myeloma diagnosis according to the IMWG diagnostic criteria. b. Measurable disease at screening as assessed by central laboratory, defined by any of the following: 1. Serum M-protein level =0.5 g/dL (central laboratory); or 2. Urine M-protein level =200 mg/24 hours (central laboratory); or 3. Light chain multiple myeloma without measurable M protein in the serum or the urine: serum immunoglobulin free light chain =10 mg/dL (central laboratory) and abnormal serum immunoglobulin kappa lambda free light chain ratio (central laboratory), Relapsed or refractory disease as defined below: a. Relapsed disease is defined as an initial response to prior treatment, followed by confirmed progressive disease by IMWG criteria >60 days after cessation of treatment. b. Refractory disease is defined as <25% reduction in M-protein or confirmed progressive disease by IMWG criteria during previous treatment or =60 days after cessation of treatment., Documented evidence of progressive disease or failure to achieve a minimal response to the last line of therapy based on investigator’s determination of response by IMWG criteria on or after their last regimen., Have an ECOG performance status score of 0, 1, or 2 at screening and immediately prior to the start of administration of study treatment.
排除标准
- •Contraindications or life-threatening allergies, hypersensitivity, or intolerance to any study drug or its excipients (refer to the talquetamab IB, teclistamab IB, and appropriate prescribing information)., Stroke, transient ischemic attack, or seizure within 6 months prior to signing ICF., Presence of the following cardiac conditions: a. New York Heart Association Class III or IV congestive heart failure b. Myocardial infarction, unstable angina, or coronary artery bypass graft =6 months prior to randomization c. History of clinically significant ventricular arrhythmia or unexplained syncope, not believed to be vasovagal in nature or due to dehydration d. History of severe non-ischemic cardiomyopathy, Major surgery or had significant traumatic injury within 2 weeks prior to the start of administration of study treatment, or will not have fully recovered from surgery, or has major surgery planned during the time the participant is expected to be treated in the study or within 2 weeks after administration of the last dose of study treatment., Prior or concurrent exposure to any of the following, in the specified time frame prior to randomization: o T cell redirection therapy (for example, antibody therapy or BiTEs) within 3 months o Gene-modified adoptive cell therapy (e.g., chimeric antigen receptor modified T cells, NK cells) within 3 months o Targeted therapy, epigenetic therapy, mAb therapy, cytotoxic therapy, or treatment with an investigational drug or an invasive investigational medical device within 21 days or =5 half-lives, whichever is less o Investigational vaccine other than SARS CoV-2 vaccine approved or authorized for emergency use within 4 weeks o Live, attenuated vaccine within 4 weeks. Non-live and non-replicating vaccines approved or authorized for emergency use (e.g., COVID-19) by local health authorities are allowed. o PI therapy within 14 days o IMiD agent therapy within 14 days o Focal radiation within 7 days
研究者
相似试验
招募中
3 期
A Phase 3 Randomized Study Comparing Talquetamab in Combination with Daratumumab (SC) and Pomalidomide (Tal-DP) or Talquetamab (SC) in combination with Daratumumab SC (Tal-D) versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of Therapy10018865Multiple MyelomaNL-OMON53729Janssen-Cilag25
招募中
3 期
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants with Relapsed or Refractory Myeloma who Have Received an Anti-CD38 Antibody and LenalidomideCTRI/2024/02/063266Johnson and Johnson Private Limited
招募中
1 期
A Randomized Study Comparing Talquetamab in Combination WithDaratumumab and Pomalidomide or Talquetamab in Combination WithDaratumumab Versus Daratumumab, Pomalidomide and Dexamethasone, in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of TherapyMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Multiple MyelomaEUCTR2021-000202-22-NLJanssen-Cilag International NV810
进行中（未招募）
1 期
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of TherapyRelapsed or Refractory Multiple MyelomaMedDRA version: 21.1Level: PTClassification code: 10035226Term: Plasma cell myeloma Class: 100000004864CTIS2023-503467-41-00Janssen - Cilag International813
进行中（未招募）
1 期
A Randomized Study Comparing Talquetamab in Combination WithDaratumumab and Pomalidomide or Talquetamab in Combination WithDaratumumab Versus Daratumumab, Pomalidomide and Dexamethasone, in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of TherapyMultiple MyelomaEUCTR2021-000202-22-FRJanssen-Cilag International NV810